This study will characterize the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of AUY922 in adult patients with advanced solid malignancies in Japan.

Inclusion Criteria:

• Patients with advanced malignant solid tumors
• ECOG Performance Status of ≤ 2
• Patients must have the following laboratory values:
• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Hemoglobin (Hgb) ≥ 8.5 g/dl, Platelets (plt) ≥ 100 x 109/L
• Potassium, Calcium, Magnesium, Phosphorus within normal limits or correctable with supplements
• AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN)
• Serum bilirubin ≤ 1.5 x ULN, Serum albumin > 2.5g/dl, Serum creatinine≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min
• Able to sign informed consent and to comply with the protocol

Exclusion Criteria:

• Patients with brain metastasis.
• Prior treatment with any HSP90 or HDAC inhibitor compound.
• Treatment with therapeutic doses of coumarin anticoagulants.
• Pregnant and lactating women.
• Severe and/or uncontrolled acute or chronic liver disease
• Severe and/or uncontrolled acute or chronic renal disease
• Chronically significant heart disease
• History (or family history) of long QT syndrome. QTc ≥ 450 msec on screening ECG, ischemic heart disease, heart fail, ECG abnormalities, atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
• Patients who are currently receiving treatment with any medication which has a relative risk or prolonging the QTcF interval or inducing Torsades de Pointes
• Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g Gilbert's syndrome).

Other protocol-defined inclusion/exclusion criteria may apply